Bevacizumab for recurrent glioblastoma, early observations on patient outcome in the belgian medical need program
Johnny Duerinck(Universitair Ziekenhuis Brussel), Anne Rogiers(Centre Hospitalier Universitaire Brugmann), Lionel D’Hondt(CHU Dinant Godinne UCL Namur), Christine Gennigens(Centre Hospitalier Universitaire de Liège), Frank Van Fraeyenhove(ZNA Middelheim Hospital), E. Joosens(Jessa Hospital), Bart Neyns(Universitair Ziekenhuis Brussel), Paul M. Clément(Universitair Ziekenhuis Leuven), Y. Staelens(Ziekenhuis Oost-Limburg), Frank Bouttens(AZ Sint-Lucas)
Open Repository and Bibliography (University of Liège)
January 1, 2012
Cited by 1
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
|The Lancet|2017|1.2k
Lomustine and Bevacizumab in Progressive Glioblastoma
|New England Journal of Medicine|2017|994
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
|Journal of Clinical Oncology|2009|573